Dicot Pharma
Uppsala
About Dicot Pharma
Dicot Pharma develops LIB-01 to become a new modern potency drug for the global market. The goal is to develop a completely new generation potency drugs that surpass currently available treatments. With a longer duration of action, fewer adverse effects, and a differentiated mode of action, Dicot Pharma aims to significantly improve the treatment of erectile dysfunctions and provide affected men and couples with a better quality of life. The company's lead candidate, LIB-01, is in clinical phase 2a. Ticker Nasdaq First North Stockholm: "DICOT"
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $12.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2024)
- Ticker: sto:DICOT
- Website: dicotpharma.com
- Phone: +46 (0) 72-502 1010
Industries & Categories
Health Care, Lifestyle, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/dicot-pharma-28947 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.